ZYRTEC HIVES RELIEF Drug Patent Profile

When do Zyrtec Hives Relief patents expire, and what generic alternatives are available?

Zyrtec Hives Relief is a drug marketed by J And J Consumer Inc and is included in one NDA.

The generic ingredient in ZYRTEC HIVES RELIEF is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and fifty-four suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zyrtec Hives Relief

A generic version of ZYRTEC HIVES RELIEF was approved as cetirizine hydrochloride by PADAGIS US on June 17^th, 2008.

Summary for ZYRTEC HIVES RELIEF

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	30
Patent Applications:	2,616
Formulation / Manufacturing:	see details
DailyMed Link:	ZYRTEC HIVES RELIEF at DailyMed

Recent Clinical Trials for ZYRTEC HIVES RELIEF

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Emory University	Phase 4
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division	Phase 1
Indiana University	Phase 4

See all ZYRTEC HIVES RELIEF clinical trials

Pharmacology for ZYRTEC HIVES RELIEF

Drug Class	Histamine-1 Receptor Antagonist
Mechanism of Action	Histamine H1 Receptor Antagonists

US Patents and Regulatory Information for ZYRTEC HIVES RELIEF

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
J And J Consumer Inc	ZYRTEC HIVES RELIEF	cetirizine hydrochloride	TABLET;ORAL	019835-005	Nov 16, 2007		DISCN	Yes	No
J And J Consumer Inc	ZYRTEC HIVES RELIEF	cetirizine hydrochloride	TABLET;ORAL	019835-006	Nov 16, 2007		DISCN	Yes	No

International Patents for ZYRTEC HIVES RELIEF

See the table below for patents covering ZYRTEC HIVES RELIEF around the world.

Country	Patent Number	Title	Estimated Expiration
U.S.S.R.	1310397	"2- 4-(_ДИФEHИЛMETИЛ)-1-ПИПEPAЗИHИЛ -УKCУCHЫE KИCЛOTЫ ИЛИ ИX AMИДЫ,ИЛИ ИX HETOKCИЧHЫE ФAPMAЦEBTИЧECKИ ПPИEMЛEMЫE COЛИ,ПPOЯBЛЯЮЩИE CПAЗMOЛИTИЧECKУЮ И AHTИГИCTAMИHHУЮ AKTИBHOCTЬ" (2-/4-(DIPHENYLMETHYL)-1-PIPERAZINYL/-ACETIC ACIDS OR THEIR AMIDES,OR THEIR NONTOXIC PHARMACEUTICALLY ACCEPTABLE SALTS SHOWING SPASMOLYTIC AND ANTIHISTAMINIC ACTIVITY)
Australia	544066
Lithuania	2553
Japan	S6311353

Supplementary Protection Certificates for ZYRTEC HIVES RELIEF

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0058146	SPC/GB01/052	United Kingdom		SPC/GB01/052:, EXPIRES: 20070205
0058146	2001C/045	Belgium		PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
0663828	C300085	Netherlands		PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103